Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02037945 · ClinicalTrials.gov registry record · NA
18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT02037945: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02037945 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02037945, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the distribution of 18F Fluorocholine (18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth. In addition, the study will measure levels of 18F-FCH in the blood and (if applicable) in the brain lesion tissue that is removed as part of the planned brain surgery.
Primary Outcome
by comparing the PET imaging results to the surgical pathology
Interventions
- PROCEDURE 18F-FCH PET Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-01 |
| Est. Completion | 2022-12-08 |
| Phase | NA |
What the finished NCT02037945 record still lists
NCT02037945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which 18F-FCH PET Scan is the first listed.
NCT02037945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02037945 about?
NCT02037945 is a clinical study titled "18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases". The main purpose of this study is to determine the distribution of 18F Fluorocholine (18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth. In addition, the study will measure levels of 18F-FCH in the blood and (if applicable) in the brain lesion tissue ...
What is the current status of trial NCT02037945?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2014-01. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT02037945?
The interventions under investigation include: 18F-FCH PET Scan (PROCEDURE).
Who is sponsoring clinical trial NCT02037945?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02037945's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia